Friday was a good day for Gilead Sciences ( GILD). Not only did it win U.S. marketing approval late Friday for a new drug to treat a life-threatening lung disease, but the drug's FDA-approved label should also give the company an advantage over its competition.The drug, ambrisentan, which will now go by the brand name Letairis, will be used to treat pulmonary arterial hypertension (PAH), a chronic disease caused by constriction of the blood vessels that bring blood from the heart to the lungs. The disease affects about 200,000 patients worldwide. However, Friday was a bad day for Encysive Pharmaceuticals ( ENCY), which failed yet again to convince the FDA to approve its PAH drug Thelin. U.S. drug regulators sent Encysive its third "approvable letter" on Thelin, this time telling the company that it lacked enough evidence of efficacy to justify approval. Before the FDA announcements, Gilead and Encysive shares closed Friday at $80.83 and $4.10, respectively. In Monday's premarket, Gilead shares traded for about $82, while Encysive shares were at $2.10. With Encysive out of the way, Gilead's competition for PAH patients will come mainly from Tracleer, an older drug sold by Actelion. And that's a very good thing for Gilead, because the FDA-approved label for Letairis includes efficacy and safety data that show the drug to be best in class, with significant advantages over Tracleer. Last year, Actelion booked Tracleer sales totaling $722 million. This year, the company is on track to sell about $800 million of the drug. But not everything went Gilead's way Friday. Letairis' label does include a so-called "black box" warning regarding potential serious liver damage in patients treated with the drug. As a result, patients will be required to undergo monthly liver safety monitoring. In an
-- about $3,940 per month -- and will launch the drug this week.